Table 4.
Adverse reactions of patients enrolled in our study n (%)
| Adverse reaction |
Chemoembolization (n = 92) |
Chemoembolization + HAIC (n = 137) |
||||
| I + II | III + IV | I + II | III + IV | P1 | P2 | |
| Hematologic toxicity | ||||||
| Reduction of white cells | 13 (14.1) | 0 | 21 (15.3) | 2 (1.4) | 0.803 | - |
| Reduction of hemoglobin | 17 (18.5) | 3 (3.3) | 21 (15.3) | 2 (1.4) | 0.530 | 0.393 |
| Reduction of thrombocyte | 19 (20.7) | 7 (7.6) | 57 (41.6) | 5 (3.6) | 0.001 | 0.231 |
| Non-hematologic toxicity | ||||||
| Increase of total bilirubin | 38 (41.3) | 4 (4.3) | 74 (54.0) | 5 (3.6) | 0.059 | 0.744 |
| Increase of glutamate pyruvate transaminase | 55 (59.8) | 5 (5.4) | 78 (56.9) | 11 (8.0) | 0.668 | 0.450 |
| Increase of glutamic-oxaloacetic transaminase | 50 (54.3) | 8 (8.7) | 82 (59.8) | 9 (6.5) | 0.408 | 0.547 |
| Fever | 55 (59.8) | 11 (12.0) | 64 (46.7) | 12 (8.8) | 0.052 | 0.430 |
| Pain1 | 40 (43.5) | 3 (3.3) | 63 (46.0) | 19 (13.9) | 0.708 | 0.008 |
| Nausea | 47 (51.1) | 3 (3.3) | 91 (66.4) | 5 (3.6) | 0.030 | 0.875 |
| Vomit | 19 (20.7) | 0 | 47 (34.3) | 3 (2.2) | 0.025 | - |
| Diarrhea | 1 (1.1) | 0 | 4 (3.0) | 0 | 0.768 | - |
| Constipation | 18 (19.6) | 1 (1.1) | 29 (21.2) | 0 | 0.6513 | - |
| Neurotoxicity2 | - | - | 13 (6.8) | 0 | - | - |
1
Pain was evaluated according to the grading standards for acute and subacute toxicity reactions for anti-cancer drugs issued by the WHO;
2
Neurotoxicity was evaluated according to the Levi special grading standard for sensory nerve toxicity;
3
Fisher’s exact testing method, χ2 test (P1 value: comparison of grades I + II adverse reactions between the two groups; P2 value: comparison of grades III + IV adverse reactions between the two groups). Statistics for adverse events: Evaluation based on the NCI - CTCAE v3.0 criteria. P-values: Pearson method, χ2 test.